Physician profile
Julia E Gomez
NPI 1174576599
$17,997.24
in general payments reported to CMS, 2019-2025
63 companies · $821 in 2025
The $821 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,131 · 2020: $2,021 · 2021: $3,772 · 2022: $3,068 · 2023: $3,049 · 2024: $2,136 · 2025: $821.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,006.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,005.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,030.84 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $1,728.87 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Amgen INC. | $1,456.34 | 2019-2024 | Otezla, Repatha, Prolia |
| Glaxosmithkline, LLC. | $1,214.02 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $1,179.52 | 2019-2024 | |
| Abbvie INC. | $1,152.66 | 2021-2024 | |
| Lilly USA, LLC | $1,113.19 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Astellas Pharma US INC | $908.05 | 2019-2024 | Veozah, Myrbetriq |
| Merck Sharp & Dohme LLC | $596.37 | 2019-2024 | Gardasil 9, Gardasil, Capvaxive |
| Allergan, INC. | $498.03 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $460.03 | 2019-2024 | Jardiance, Synjardy |
| Novartis Pharmaceuticals Corporation | $459.57 | 2019-2023 | |
| Exact Sciences Corporation | $396.61 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Esperion Therapeutics, INC. | $382.22 | 2020-2023 | Nexletol |
| Abbott Laboratories | $380.90 | 2019-2024 | Freestyle Libre 3 |
Show all 63 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julia Gomez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.